Securities code: 688366 Securities abbreviation: Haohaishengke Announcement No.: 2025-014

Shanghai Haohai Biotechnology Co., Ltd

Announcement on the resignation of the company's core technical personnel

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Important Content Notes:

Mr. Gan Renbao, the core technical personnel of Shanghai Haohai Biotechnology Co., Ltd. (hereinafter referred to as "the company"), is no longer the core technical personnel of the company due to his advanced age, and he has completed the handover procedures for related work.

As of the date of this announcement, Mr. Gan Renbao has not participated in the company's research projects, and his resignation will not have a substantial impact on the company's technology research and development, production and operation, will not affect the core technology held by the company, and there are no disputes or potential disputes involving service inventions.

First, the specific situation of the resignation of core technical personnel

Mr. Gan Renbao, the company's core technical personnel, no longer serves as the company's core technical personnel due to his advanced age. The Company and the Board of Directors would like to express their gratitude to Mr. Gan Renbao for his work for the development of the Company.

(1) The basic situation of core technical personnel

Gan Renbao, male, born in 1939, Chinese nationality, no right of abode abroad, bachelor's degree, doctoral supervisor

Division. From October 1960 to June 2004, he successively served as a biochemist at the Shanghai Institute for Biological Sciences, Chinese Academy of Sciences

Researcher and cadre of the Institute of Cell Biology. Mr. Gan Renbao joined the Company in July 2010 and served as the Deputy General Manager, Director and Non-executive Director of the Company, and was a core technical personnel of the Company before leaving the Company.

As of the disclosure date of this announcement, Mr. Gan Renbao did not hold any shares of the Company.

(2) R&D projects and patents in which Mr. Gan Renbao participated

During his tenure in the company, Mr. Gan Renbao applied for and obtained a total of 2 authorized service invention patents as an inventor. None of the aforesaid invention patents are owned by a single inventor and are owned by the company. There is no dispute or potential dispute between Mr. Gan Renbao and the Company involving the ownership of intellectual property rights such as service invention patents, and the resignation of Mr. Gan Renbao will not affect the integrity of the Company's patents and other intellectual property rights, and will not cause significant problems to the Company's business development and technological innovation

positive impact.

As of the disclosure date of this announcement, Mr. Gan Renbao has not participated in the company's research and development projects, and Mr. Gan Renbao's resignation will not affect the promotion and implementation of the company's research projects and core technologies.

(3) Confidentiality agreements

The Company has signed a Confidentiality Agreement with Mr. Gan Renbao, and according to the Confidentiality Agreement signed with the Company, Mr. Gan Renbao shall be obliged to keep confidential the technical secrets or business secrets belonging to the Company that he has come into contact with and learned during his tenure in the Company for any reason. You shall not disclose, inform, publish, publish, impart, transfer or otherwise make any third party aware of the technical secrets or trade secrets belonging to the Company.

As of the date of this announcement, the Company has not found any situation in which Mr. Gan Renbao went to work for a competitor after leaving his job, or violated the Confidentiality Agreement or confidentiality clauses.

Second, the impact of the resignation of core technical personnel on the company

Mr. Gan Renbao has not participated in the company's research projects at present, and the existing core technical personnel and R&D team can support the company's continuous research and development of core technologies in the future. The resignation of Mr. Gan Renbao will not have a material impact on the Company's technology research and development, core competitiveness and ability to continue operations.

The company's R&D team has a complete structure and sufficient reserve personnel. Company late 2022, late 2023, 2024

At the end of the year, the number of R&D personnel was 344, 366 and 350 respectively, and the number of R&D personnel was relatively stable.

As of December 31, 2024, the number of R&D personnel in the company is 350, accounting for about the total number of employees in the company

16.23%, including 25 with doctoral degree and 107 with master's degree.

As of the disclosure date of this announcement, the specific situation of the company's core technical personnel is as follows:

Name of the core technical personnel

Before this change, Hou Yongtai, Wei Changzheng, Zhang Jundong, Wang Wenbin, Gan Renbao, Jiang Lixia, Du

Peng, Liu Lu, Yueai Liu, Tristan Trevelyan Tapper

After this change, Hou Yongtai, Wei Changzheng, Zhang Jundong, Wang Wenbin, Jiang Lixia, Du Peng, Liu

Lu, Yueai Liu, Tristan Trevelyan Tapper

3. Measures taken by the Company

Through years of independent research and development experience, the company has formed a complete set of research and development project management and control system, team members perform their duties and finally form collective results, there is no dependence on specific technical personnel. The company's core technology

The technical staff and R&D team continue to invest in the research and development of the company's products and technologies.

At present, the company's R&D team has a complete structure, sufficient reserve personnel, and R&D projects are in a normal and orderly state, and the existing core technical personnel and R&D team can support the company's continuous R&D work of core technologies in the future. The company attaches great importance to R&D, continuously invests in R&D, improves R&D system and cultivates R&D talents, and continuously improves the company's technological innovation capabilities.

The announcement is hereby made.

Board of Directors of Shanghai Haohai Biotechnology Co., Ltd

March 29, 2025